
Marc A Ilies

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7513210/publications.pdf Version: 2024-02-01



MARC A LUES

#	Article	IF	CITATIONS
1	Evaluation of the Impact of Esterases and Lipases from the Circulatory System against Substrates of Different Lipophilicity. International Journal of Molecular Sciences, 2022, 23, 1262.	1.8	5
2	PEG Linker Length Strongly Affects Tumor Cell Killing by PEGylated Carbonic Anhydrase Inhibitors in Hypoxic Carcinomas Expressing Carbonic Anhydrase IX. International Journal of Molecular Sciences, 2021, 22, 1120.	1.8	8
3	Efflux pumps, NHE1, monocarboxylate transporters, and ABC transporter subfamily inhibitors. , 2021, , 95-120.		0
4	Carbonic Anhydrases as Potential Targets Against Neurovascular Unit Dysfunction in Alzheimer's Disease and Stroke. Frontiers in Aging Neuroscience, 2021, 13, 772278.	1.7	27
5	Structural Basis of Nanomolar Inhibition of Tumor-Associated Carbonic Anhydrase IX: X-Ray Crystallographic and Inhibition Study of Lipophilic Inhibitors with Acetazolamide Backbone. Journal of Medicinal Chemistry, 2020, 63, 13064-13075.	2.9	26
6	Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII. Bioorganic Chemistry, 2020, 103, 104204.	2.0	24
7	Carbonic anhydrase inhibitors for the treatment of tumors. , 2019, , 331-365.		3
8	Carbonic anhydrases as disease markers. Expert Opinion on Therapeutic Patents, 2019, 29, 509-533.	2.4	51
9	Drug Delivery to Hypoxic Tumors Targeting Carbonic Anhydrase IX. ACS Symposium Series, 2019, , 223-252.	0.5	1
10	Choline Is an Intracellular Messenger Linking Extracellular Stimuli to IP3-Evoked Ca2+ Signals through Sigma-1 Receptors. Cell Reports, 2019, 26, 330-337.e4.	2.9	45
11	Crystal Structure of Carbonic Anhydrase II in Complex with an Activating Ligand: Implications in Neuronal Function. Molecular Neurobiology, 2018, 55, 7431-7437.	1.9	26
12	Potential learning and memory disruptors and enhancers in a simple, 1-day operant task in mice. Behavioural Pharmacology, 2018, 29, 482-492.	0.8	11
13	pH-Sensitive Multiligand Gold Nanoplatform Targeting Carbonic Anhydrase IX Enhances the Delivery of Doxorubicin to Hypoxic Tumor Spheroids and Overcomes the Hypoxia-Induced Chemoresistance. ACS Applied Materials & Interfaces, 2018, 10, 17792-17808.	4.0	50
14	Potential Model of Carbonic Anhydrase Effects on Learning and Memory. FASEB Journal, 2018, 32, 551.3.	0.2	0
15	Determining Key Carbonic Anhydrase Isozymes Involved in Learning and Memory via Mouse Memory Assays. FASEB Journal, 2018, 32, 551.2.	0.2	0
16	Interfacially Engineered Pyridinium Pseudogemini Surfactants as Versatile and Efficient Supramolecular Delivery Systems for DNA, siRNA, and mRNA. ACS Applied Materials & Interfaces, 2017, 9, 29481-29495.	4.0	13
17	Interface-Engineered Amphiphilic Block Copolymers with Tuned Enzymatic Resistance for Controlled Delivery of Chemotherapeutic Drugs. ACS Symposium Series, 2017, , 211-229.	0.5	0
18	Synthetic Delivery Systems for DNA, siRNA, and mRNA Based on Pyridinium Amphiphiles. ACS Symposium Series, 2017, , 1-34.	0.5	6

MARC A ILIES

#	Article	IF	CITATIONS
19	PEGylated Bis-Sulfonamide Carbonic Anhydrase Inhibitors Can Efficiently Control the Growth of Several Carbonic Anhydrase IX-Expressing Carcinomas. Journal of Medicinal Chemistry, 2016, 59, 5077-5088.	2.9	53
20	Supersaturated controlled release matrix using amorphous dispersions of glipizide. International Journal of Pharmaceutics, 2016, 511, 957-968.	2.6	18
21	Efficient and synergetic DNA delivery with pyridinium amphiphiles–gold nanoparticle composite systems having different packing parameters. Chemical Communications, 2016, 52, 60-63.	2.2	8
22	Synthetic Nucleic Acid Delivery Systems: Present and Perspectives. Journal of Medicinal Chemistry, 2015, 58, 4091-4130.	2.9	78
23	Solid-State Interactions at the Core-Coat Interface: Physicochemical Characterization of Enteric-Coated Omeprazole Pellets Without a Protective Sub-Coat. AAPS PharmSciTech, 2015, 16, 934-943.	1.5	9
24	Heterocyclic Cationic Gemini Surfactants: A Comparative Overview of Their Synthesis, Selfâ€assembling, Physicochemical, and Biological Properties. Medicinal Research Reviews, 2014, 34, 1-44.	5.0	75
25	Modulation of Pyridinium Cationic Lipid–DNA Complex Properties by Pyridinium Gemini Surfactants and Its Impact on Lipoplex Transfection Properties. Molecular Pharmaceutics, 2014, 11, 545-559.	2.3	46
26	Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect. Chemical Communications, 2014, 50, 5980-5983.	2.2	48
27	New Synthetic Strategies for the Management of Chagas Disease (American Trypanosomiasis). Journal of Medicinal Chemistry, 2014, 57, 296-297.	2.9	1
28	Interfacial engineering of pyridinium gemini surfactants for the generation of synthetic transfection systems. Biomaterials, 2013, 34, 6906-6921.	5.7	30
29	Tuning the Self-Assembling of Pyridinium Cationic Lipids for Efficient Gene Delivery into Neuronal Cells. Biomacromolecules, 2013, 14, 2750-2764.	2.6	18
30	Enzyme and acid catalyzed degradation of PEG45-b-PBO0,6,9-b-PCL60 micelles: Increased hydrolytic stability by engineering the hydrophilic–hydrophobic interface. Polymer, 2013, 54, 2879-2886.	1.8	6
31	Modifying the Hydrophilic–Hydrophobic Interface of PEG- <i>b</i> PCL To Increase Micelle Stability: Preparation of PEG- <i>b</i> PBO- <i>b</i> PCL Triblock Copolymers, Micelle Formation, and Hydrolysis Kinetics. Macromolecules, 2012, 45, 660-665.	2.2	33
32	Stabilization of Soft Lipid Colloids: Competing Effects of Nanoparticle Decoration and Supported Lipid Bilayer Formation. ACS Nano, 2011, 5, 2619-2628.	7.3	57
33	Supported Lipid Bilayer NanoSystems: Stabilization by Undulatory-Protrusion Forces and Destabilization by Lipid Bridging. Langmuir, 2011, 27, 5850-5861.	1.6	17
34	Endothelial Targeting of Antibody-Decorated Polymeric Filomicelles. ACS Nano, 2011, 5, 6991-6999.	7.3	102
35	Pyridinium derivatives of histamine are potent activators of cytosolic carbonic anhydrase isoforms I, II and VII. Organic and Biomolecular Chemistry, 2011, 9, 2790.	1.5	29
36	Pyridinium Amphiphiles in Gene Delivery – Present and Perspectives. ACS Symposium Series, 2011, , 23-38.	0.5	8

MARC A ILIES

#	Article	IF	CITATIONS
37	An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isoform II. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2764-2768.	1.0	31
38	A new and efficient synthetic route for the anxiolytic agent CL285032. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 259-261.	1.0	7
39	Molecular and crystal structure of a self-assembling pyridinium cationic lipid. Journal of Molecular Structure, 2010, 984, 228-231.	1.8	8
40	Formation and Colloidal Stability of DMPC Supported Lipid Bilayers on SiO ₂ Nanobeads. Langmuir, 2010, 26, 12081-12088.	1.6	81
41	Synthesis and Retrostructural Analysis of Libraries of AB3and Constitutional Isomeric AB2Phenylpropyl Ether-Based Supramolecular Dendrimers. Journal of the American Chemical Society, 2006, 128, 3324-3334.	6.6	154
42	178. Structure-Activity Relationships in a Library of Pyridinium Non-Viral Vectors for Gene Delivery. Molecular Therapy, 2006, 13, S69.	3.7	0
43	Pyridinium cationic lipids in gene delivery: an in vitro and in vivo comparison of transfection efficiency versus a tetraalkylammonium congener. Archives of Biochemistry and Biophysics, 2005, 435, 217-226.	1.4	72
44	Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorganic and Medicinal Chemistry, 2004, 12, 2717-2726.	1.4	90
45	Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating arylsulfonylureido and 5-dibenzo-suberenyl/suberyl moieties. Bioorganic and Medicinal Chemistry, 2003, 11, 2227-2239.	1.4	28
46	Carbonic Anhydrase Inhibitors. Inhibition of Tumor-Associated Isozyme IX by Halogenosulfanilamide and Halogenophenylaminobenzolamide Derivativesâ€. Journal of Medicinal Chemistry, 2003, 46, 2187-2196.	2.9	141
47	Therapeutic applications of serine protease inhibitors. Expert Opinion on Therapeutic Patents, 2002, 12, 1181-1214.	2.4	25
48	Carbonic Anhydrase Activators:  Design of High Affinity Isozymes I, II, and IV Activators, Incorporating Tri-/Tetrasubstituted-pyridinium-azole Moieties. Journal of Medicinal Chemistry, 2002, 45, 504-510.	2.9	74
49	Cationic Lipids in Gene Delivery: Principles, Vector Design and Therapeutical Applications. Current Pharmaceutical Design, 2002, 8, 2441-2473.	0.9	59
50	Carbonic Anhydrase Inhibitors: Synthesis and Inhibition Against Isozymes I, II and IV of Topically Acting Antiglaucoma Sulfonamides Incorporating <i>cis</i> -5-Norbornene- <i>endo</i> -3-Carboxy-2-Carboxamido Moieties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 113-123.	0.5	8
51	Protease inhibitors. European Journal of Pharmaceutical Sciences, 2000, 11, 69-79.	1.9	16
52	Protease Inhibitors: Part 4. Synthesis of Weakly Basic Thrombin Inhibitors Incorporating Pyridinium-Sulfanilylaminoguanidine Moieties. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 335-356.	0.5	2
53	Carbonic Anhydrase Inhibitors; Phosphoryl-Sulfonamides-A New Class of High Affinity Inhibitors of Isozymes I and II. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 297-309.	0.5	9
54	Carbonic Anhydrase Inhibitors: Synthesis of Sulfonamides Incorporating 2, 4, 6–Trisubstituted-Pyridinium-Ethylcarboxamido Moieties Possessing Membrane-Impermeability and in Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2000, 15, 381-401.	0.5	47

MARC A ILIES

#	Article	IF	CITATIONS
55	Carbonic Anhydrase Inhibitors:Â Synthesis of Membrane-Impermeant Low Molecular Weight Sulfonamides Possessing in Vivo Selectivity for the Membrane-Bound versus Cytosolic Isozymes1. Journal of Medicinal Chemistry, 2000, 43, 292-300.	2.9	147
56	Carbonic Anhydrase Inhibitors:Â Water-Soluble 4-Sulfamoylphenylthioureas as Topical Intraocular Pressure-Lowering Agents with Long-Lasting Effects. Journal of Medicinal Chemistry, 2000, 43, 4884-4892.	2.9	143
57	Carbonic anhydrase inhibitors - Part 49: Synthesis of substituted ureido and thioureido derivatives of aromatic/heterocyclic sulfonamides with increased affinities for isozyme I. European Journal of Medicinal Chemistry, 1998, 33, 83-93.	2.6	152
58	Carbonic anhydrase inhibitors — Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV. European Journal of Medicinal Chemistry, 1998, 33, 577-594.	2.6	74
59	Carbonic anhydrase inhibitors — Part 29 1: Interaction of isozymes I, II and IV with benzolamide-like derivatives. European Journal of Medicinal Chemistry, 1998, 33, 739-751.	2.6	135
60	Carbonic anhydrase inhibitors — Part 52. Metal complexes of heterocyclic sulfonamides: A new class of strong topical intraocular pressure-lowering agents in rabbits. European Journal of Medicinal Chemistry, 1998, 33, 247-254.	2.6	131
61	Carbonic Anhydrase Inhibitors. Part 551 Metal Complexes of 1,3,4-Thiadiazole-2-Sulfonamide Derivatives: In Vitro Inhibition Studies With Carbonic Anhydrase Isozymes I, II and IV. Metal-Based Drugs, 1998, 5, 103-114.	3.8	11
62	SYNTHESIS AND CARBONIC ANHYDRASE INHIBITORY ACTIVITY OF 5-BENZOYLAMIDO- AND 5-(3-NITROBENZOYLAMIDO)- 1,3,4-THIADIAZOLE-2-SULFONAMIDE AND THEIR METAL COMPLEXES. Main Group Metal Chemistry, 1997, 20, .	0.6	43